Thread Bancorp, Inc. Welcomes Dan Chang as New General Counsel and Chief Compliance Officer, Supporting Expansion of Embedded Banking Services
THRD(NASDAQ:THRD) NASHVILLE, Tenn.--(BUSINESS WIRE)--Thread Bancorp, Inc. (“Thread” or the “Company”), the parent company of Thread Bank (the “Bank”), today announced the appointment of Dan Chang as General Counsel and Chief Compliance Officer. Chang will lead regulatory and compliance oversight, overseeing the Bank’s continued commitment to regulatory soundness as it broadens the range of consumer and commercial services offered through its embedded banking platform. Chang joins Thread from Splash Financial, In
Thread Bancorp, Inc. Welcomes Marty Miracle as Chief Digital Officer to Drive Scalable, Compliant Embedded Banking Innovation
THRDNASHVILLE, Tenn.--(BUSINESS WIRE)--Thread Bancorp, Inc. and Thread Bank (together, “Thread”) today announced the appointment of Marty Miracle as Chief Digital Officer, further reinforcing Thread’s commitment to digital transformation and technology-driven growth. In this executive role, Miracle will lead the development and execution of Thread’s digital strategy, building on its strong foundation of embedded, business, and personal banking solutions. Miracle joins Thread from Sutton Bank, where
Third Harmonic Bio Announces Stockholder Approval Of Liquidation And Dissolution Plan With Initial Distribution Expected In The Range Of $5.30-$5.35; Co. Initiates Sale Process Of THB335
THRDThird Harmonic Bio Q1 EPS $(0.35) Misses $(0.29) Estimate
THRDThird Harmonic Bio Stock Is Up 40% Monday: What's Happening?
THRDThird Harmonic Bio Inc (NASDAQ:THRD) shares are soaring on Monday after the company announced a plan of liquidation and dissolution.
Third Harmonic Bio Announces Plan Of Dissolution With Payout Between $246.6M–$255.4M Pending Stockholder Approval
THRDStifel Downgrades Third Harmonic Bio to Hold, Lowers Price Target to $5
THRDThird Harmonic Bio FY 2024 GAAP EPS $(1.09) Beats $(1.18) Estimate
THRDThird Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
THRDThird Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% while reviewing strategic options.
Third Harmonic Bio, Inc. IPOs Tomorrow, Here's What You Need To Know
THRDThird Harmonic Bio, Inc. (NASDAQ:THRD) IPO will take place September, 15 on the NASDAQ exchange under the ticker THRD.
The company is offering shares at an expected price between $16.00 and $18.00 per share with an insider lock-up period of 180 days ending on March 14, 2023.